Clinical trials: Incretins
Diabetes Mellitus, Type 2
Incretin-based Drugs and Acute Pancreatitis
The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone or in combination with other anti-diabetic drugs are associated with an increased risk of acute…
- Trial name
- NCT02476760
- Testing
- DPP-4 inhibitors, GLP-1 analogs, Insulins
- Where
- Canada
- Volunteers
- 1,417,914 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Diabetes, Obesity
AIManage Using an AI-driven CDS and Chatbot
The objective of this project is to define and test the GenAI-powered Clinical Decision Support (CDS) tool, AIManage, providing a broad range of incretin mimetic medication management services to optimize dose titrations.
- Conditions
- Diabetes, Obesity, Medication Side Effects
- Trial name
- NCT07546357
- Testing
- AIManage
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- NYU Langone Health
Caloric Restriction, Body Composition
Long-Term Effects of Semaglutide on Body Composition and Performance in Running
Semaglutide, a GLP-1 receptor agonist, has demonstrated significant weight-loss effects in people with obesity and/or type 2 diabetes, but its impact on exercise performance among lean, fit athletes remains unknown.
- Conditions
- Caloric Restriction, Body Composition, Performance
- Trial name
- NCT07874932
- Testing
- Semaglutide (SEMA)
- Where
- Denmark
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Morten Hostrup, PhD
Obesity and Obesity-related Medical Conditions, Obesity and Overweight
MAINTAIN (Mucosal AblatIoN Therapy After INcretins)
The purpose of this study is to assess the effect of gastric fundal mucosal ablation (GFMA) on weight trajectory following discontinuation of once-weekly semaglutide or tirzepatide in adults with obesity.
- Conditions
- Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Obesity Prevention, Obesity Recidivism
- Trial name
- MAINTAIN (NCT06734312)
- Testing
- Gastric Fundal Mucosal Ablation (GFMA)
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dr. Christopher McGowan
Healthy Subjects, Gastric Emptying
GLP-1 - Regulatory Mechanism of Postprandial Glycemia
Synthetic GLP-1 lowers postprandial (pp) glycemia by stimulating insulin, inhibiting glucagon, and delaying gastric emptying. However, the effects of the endogenous peptide are largely unknown.
- Trial name
- NCT00980083
- Testing
- Saline, Exendin(9-39)amide
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Ludwig-Maximilians - University of Munich
Quality of Life
Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients
A diminution of quality of life is often reported by patients after coronary artery bypass graft (CABG) surgery. A part of this diminution could be explain by postoperative left ventricular (LV) dysfunction.
- Trial name
- ExeQOL (NCT02432976)
- Testing
- Exenatide, Insulin
- Where
- France
- Volunteers
- 64 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Incretin Effect
The Effect of GIP, GLP-1 and GLP-2 in Individuals With Genetically Altered Receptor Function
This project will characterize the physiological effect of the hormones, GIP-, GLP-1- and GLP-2 infusions in a group of individuals that are carriers of GIP-, GLP-1- and GLP-2 receptor gene variants, respectively.
- Trial name
- H-21044858 (NCT06194955)
- Testing
- GIP(1-42), GLP-1, GLP-2
- Where
- Denmark
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Type 2 Diabetes
Short-term Effect of Intensive Insulin Therapy on Incretin Secretion
In type 2 diabetic patients, abnormality in secretion or action of incretin(GLP-1, GIP) is observed. Although controversy still exists, the secretion of GLP-1 is thought to be reduced by 20-30% while GIP secretion is normal or…
- Trial name
- NCT00776243
- Where
- 2 sites in South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The Catholic University of Korea
Metabolic Health, Gut Hormones
Breaking Sitting and Metabolic Health in Sedentary Overweight and Obese Adults
The purpose of this project is to investigate the effects of breaking up prolonged sitting on postprandial metabolic responses, gut hormones secretion and energy balance in sedentary overweight and obese adults.
- Conditions
- Metabolic Health, Gut Hormones, Energy Balance
- Trial name
- NCT05306678
- Testing
- Prolonged sitting, Breaking sitting
- Where
- Taiwan
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- National Taiwan Normal University
Type 1 Diabetes Mellitus
Incretin Hormones in Type 1 Diabetes Mellitus;Effect of Metformin Treatment
Investigators aim is to conduct an RCT to study the effect of adjunct metformin treatment to insulin monotherapy in patients with type 1 diabetes, targeting the intestinal incretin secretion.
- Trial name
- INCREDIBLE-M (NCT04177303)
- Testing
- Metformin
- Where
- Greece
- Volunteers
- 44 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Type 2 Diabetes Mellitus
Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients
Specific Aim 1.To examine whether the combination of liraglutide plus canagliflozin can prevent the increase in Hepatic Glucose Production (HGP) following institution of canagliflozin therapy and produce an additive or even…
- Trial name
- NCT02324842
- Testing
- Canagliflozin, Liraglutide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Diabetes Mellitus, Diabetes Mellitus, Type 2
The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes
Glucagon-like peptide 1 (GLP-1) based therapies, such as exenatide, are already successfully employed in the treatment of Type 2 Diabetes (T2DM).
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Obesity
- Trial name
- Braini-Ex (NCT01281228)
- Testing
- exenatide, exenatide + exendin (9-39)
- Where
- Netherlands
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Type 2 Diabetes
The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics
The goal of this study was to determine the metabolic mechanism for a certain type medication's ability to lower blood sugar after a meal in Type 2 Diabetics, in order to develop a better understanding of it's potential role in…
- Trial name
- NCT00951899
- Testing
- Colesevelam, Diet, Metformin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Diabetes Mellitus, Type 2
Pioglitazone Incretin Study
Incretin hormones are hormones produced by the gut in response to food intake. These hormones help the body to control the metabolism of glucose (sugar).
- Trial name
- NCT00656864
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Vermont
Diabetes Mellitus, Type 2
Efficacy and Safety of Vildagliptin Compared to Placebo on the Incretin Effect in Patients With Type 2 Diabetes Treated With Metformin
This mechanistic study will evaluate the effect of vildagliptin on glucose-stimulated insulin secretion to improve the incretin effect in patients with type 2 diabetes.
- Trial name
- NCT00396071
- Testing
- vildagliptin
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
Study of Sulphonylurea Synergy With Incretins
The Study of Sulphonylurea Synergy with Incretins (LOGIC) is a Proof-of-Concept Physiological study in the form of two matched isoglycaemic clamps.
- Trial name
- LOGIC (NCT03705195)
- Testing
- Gliclazide
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- University of Dundee
Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction
Incretin Therapies in Obesity-related HFpEF
The central hypothesis to be tested is that patients with obesity and heart failure with preserved ejection fraction (HFpEF) prescribed tirzepatide will demonstrate reductions in measured plasma volume.
- Conditions
- Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Obesity
- Trial name
- NCT07554638
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Columbia University
Type 2 Diabetes Mellitus
Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to assess the effect of the DPP-4 inhibitor sitagliptin on the incretin effect in patients with type 2 diabetes mellitus.
- Trial name
- NCT00551590
- Testing
- Sitagliptin tablet, Saline infusion, Exendin(9-39) infusion
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Pregnancy, Postprandial Glycemia
Whey Protein Pre-load and Postprandial Glycemia in Pregnancy
This pilot study aims to investigate the intake of whey protein prior to carbohydrate intake as an approach to modulate postprandial glucose excursions during pregnancy.
- Trial name
- ProGs (NCT06170905)
- Testing
- Whey protein-preload OGTT
- Where
- Germany
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Ulm
Healthy
Sucralose Effects on Glucose Metabolism and Gut Microbiota
Hypothesis: 1. Long-term consumption of sucralose may effect glucose metabolism, incretin hormone secretion and gut microbiota in healthy adults. 2. Long-term consumption of sucralose may alter food behaviour in healthy adults.
- Trial name
- NCT02650947
- Testing
- Sucralose
- Where
- Thailand
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Ramathibodi Hospital